# MyndTec Inc.

## Interim Condensed Consolidated Financial Statements (Unaudited)

**As at June 30, 2024**

(Expressed in Canadian Dollars, unless otherwise noted)

**<u>Interim Condensed Consolidated Financial Statements</u>**


| | |
|---|---|
| Statements of Financial Position | 1 |
| Statements of Loss and Comprehensive Loss | 2 |
| Statements of Changes in Shareholders' Deficiency | 3 |
| Statements of Cash Flows | 4 |
| Notes to Financial Statements | 5 - 19 |

## MyndTec Inc.
## Interim Unaudited Condensed Consolidated Statements of Financial Position
### As at June 30, 2024 and December 31, 2023

| | June 30 2024 | December 31 2023 |
|---|---|---|
| **Assets** | | |
| **Current assets** | | |
| Cash and cash equivalents | **$ 145,418** | $ 187,411 |
| Trade and other receivables (notes 3 and 12) | **11,597** | 13,527 |
| Inventories (note 4) | **139,396** | 184,418 |
| Prepaid expenses and deposits | **35,714** | 50,653 |
| | **332,125** | 436,009 |
| **Non-current assets** | | |
| Right-of-use asset (note 5) | **1,946** | 13,622 |
| Equipment (note 6) | **94,603** | 105,217 |
| **Total assets** | **$ 428,674** | $ 554,848 |
| **Liabilities** | | |
| **Current liabilities** | | |
| Trade and other payables (notes 7 and 12) | **$ 917,389** | $ 968,117 |
| Deferred revenue (notes 8 and 12) | **17,000** | 17,000 |
| Current portion of long-term liabilities (note 9) | **434,910** | 455,511 |
| | **1,369,299** | 1,440,628 |
| **Long-term liabilities, net of current portion** | | |
| Deferred revenue (notes 8 and 12) | **25,500** | 34,000 |
| Lease obligation (note 5) | **-** | - |
| Government loans (note 10) | **-** | - |
| Other long-term debt (note 11) | **22,960** | - |
| **Total liabilities** | **1,417,759** | 1,474,628 |
| **Shareholders' deficiency** | | |
| Share capital (note 13) | **15,316,716** | 14,971,184 |
| Contributed surplus (note 13) | **4,001,904** | 3,787,802 |
| Accumulated deficit | **(20,307,705)** | (19,678,766) |
| Total deficiency | **(989,085)** | (919,780) |
| **Total liabilities and shareholders' deficiency** | **$ 428,674** | $ 554,848 |

**Nature of business and going concern (notes 1, 2, 7, 10 & 18)**

**Commitments and contingencies (note 18)**

**Subsequent events (note 22)**

____*"Craig Leon"*________ Director

___*"Bill Jackson"*________ Director

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

## MyndTec Inc.
## Interim Unaudited Condensed Consolidated Statements of Loss and Comprehensive Loss
### For the six-month and three-month periods ended June 30, 2024 and 2023

| | Three Months Ended June 30 | | Six Months Ended June 30 | |
|---|---|---|---|---|
| | **2024** | **2023** | **2024** | **2023** |
| **Revenue (notes 12 and 21)** | **$ 17,181** | $ 20,738 | **$ 86,322** | $ 59,047 |
| **Cost of sales** | **54,416** | 20,097 | **88,733** | 37,473 |
| **Gross margin** | **(37,235)** | 641 | **(2,411)** | 21,574 |
| **Expenses** | | | | |
| General and administration (note 14) | **180,101** | 210,875 | **387,791** | 409,418 |
| Research and development (note 14) | **50,183** | 144,904 | **107,727** | 239,674 |
| Quality and regulatory assurance | **4,625** | 46,574 | **5,079** | 58,674 |
| Selling and marketing | **532** | 29,624 | **952** | 59,736 |
| Share-based compensation (notes 12 and 13) | **21,977** | 46,174 | **53,120** | 73,746 |
| Interest and accretion expense (note 16) | **6,882** | 16,835 | **11,923** | 23,195 |
| Depreciation and amortization (notes 5 and 6) | **11,145** | 22,250 | **22,290** | 44,499 |
| Changes in fair value (note 16) | **(1)** | 105,436 | **(1)** | 105,436 |
| Public listing costs | **23,420** | 272,337 | **37,647** | 281,765 |
| Total operating expenses | **298,864** | 895,009 | **626,528** | 1,296,143 |
| **Net and comprehensive loss** | **$ (336,099)** | $ (894,368) | **$ (628,939)** | $ (1,274,569) |
| **Loss per share - basic and diluted** | **$ (0.01)** | $ (0.04) | **$ (0.03)** | $ (0.06) |
| **Weighted average number of common shares outstanding - basic and diluted** | **24,438,602** | 22,890,373 | **24,272,877** | 22,704,550 |

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

## MyndTec Inc.
## Interim Unaudited Condensed Consolidated Statements of Changes in Shareholders' Deficiency
### For the six-month periods ended June 30, 2024 and 2023 and the year ended December 31, 2023

| | Share Capital (note 13) | Contributed Surplus (note 13) | Accumulated Deficit | Total Deficiency |
|---|---|---|---|---|
| **Balance, December 31, 2022** | **$ 13,853,744** | **$ 3,176,353** | **$ (17,955,436)** | **$ (925,339)** |
| Net loss and comprehensive loss | - | - | (1,274,569) | (1,274,569) |
| Private placements (note 13) | 679,699 | 264,581 | - | 944,280 |
| Issuance expenses (note 13) | (29,758) | (11,570) | - | (41,328) |
| Share-based compensation | - | 73,746 | - | 73,746 |
| **Balance, June 30, 2023** | **$ 14,503,685** | **$ 3,503,110** | **$ (19,230,005)** | **$ (1,223,210)** |
| Net loss and comprehensive loss | - | - | (448,761) | (448,761) |
| Debt conversion (notes 10 and 13) | 378,062 | - | - | 378,062 |
| Private placements (note 13) | 104,960 | 166,319 | - | 271,279 |
| Issuance expenses (note 13) | (15,523) | (6,083) | - | (21,606) |
| Share-based compensation | - | 124,456 | - | 124,456 |
| **Balance, December 31, 2023** | **$ 14,971,184** | **$ 3,787,802** | **$ (19,678,766)** | **$ (919,780)** |
| Net loss and comprehensive loss | - | - | (628,939) | (628,939) |
| Private placements (note 13) | 371,285 | 171,485 | - | 542,770 |
| Issuance expenses (note 13) | (25,753) | (10,503) | - | (36,256) |
| Share-based compensation | - | 53,120 | - | 53,120 |
| **Balance, June 30, 2024** | **$ 15,316,716** | **$ 4,001,904** | **$ (20,307,705)** | **$ (989,085)** |

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

# MyndTec Inc.
## Interim Unaudited Condensed Consolidated Statements of Cash Flows
### For the six-month and three-month periods ended June 30, 2024 and 2023

| | Three Months Ended June 30 | | Six Months Ended June 30 | |
|---|---|---|---|---|
| | **2024** | **2023** | **2024** | **2023** |
| **Cash flows from (used for) operating activities** | | | | |
| Net loss and comprehensive loss | **$ (336,099)** | $ (894,368) | **$ (628,939)** | $ (1,274,569) |
| Items not affecting cash: | | | | |
| Share-based compensation | **21,977** | 46,174 | **53,120** | 73,746 |
| Depreciation and amortization (notes 5 and 6) | **11,145** | 22,250 | **22,290** | 44,499 |
| Accretion expense (note 16) | **6,162** | 3,294 | **10,711** | 10,810 |
| Changes in fair value (note 16) | **(1)** | 105,436 | **(1)** | 105,436 |
| Deferred revenue (note 8) | **(4,250)** | (4,250) | **(8,500)** | (8,500) |
| | **(301,066)** | (721,464) | **(551,319)** | (1,048,578) |
| Changes in non-cash working capital items | | | | |
| Trade and other receivables | **3,614** | (5,359) | **1,930** | 1,457 |
| Inventories | **41,407** | 19,953 | **45,022** | 38,960 |
| Prepaid expenses and deposits | **186** | 32,502 | **14,939** | (102,382) |
| Trade and other payables (note 7) | **(32,016)** | 338,820 | **(50,728)** | 346,180 |
| **Net cash used in operating activities** | **(287,875)** | (335,548) | **(540,156)** | (764,363) |
| | | | | |
| **Cash from (used for) financing activities** | | | | |
| Lease payments (note 5) | **-** | (6,762) | **(6,379)** | (13,525) |
| Repayment of deferred payment agreement (note 7) | **-** | (5,000) | **-** | (29,450) |
| Repayment of government loans (note 10) | **-** | - | **(30,000)** | - |
| Issuance of other long term debt (note 11) | **-** | - | **30,000** | - |
| Repayment of other long term debt (note 11) | **(1,188)** | - | **(1,972)** | - |
| Net proceeds of private placements (note 13) | **246,644** | 365,672 | **506,514** | 902,952 |
| **Net cash from financing activities** | **245,456** | 353,910 | **498,163** | 859,977 |
| | | | | |
| **(Decrease) increase in cash** | **(42,419)** | 18,362 | **(41,993)** | 95,614 |
| **Cash and cash equivalents, beginning of period** | **187,837** | 145,873 | **187,411** | 68,621 |
| | | | | |
| **Cash and cash equivalents, end of period** | **$ 145,418** | $ 164,235 | **$ 145,418** | $ 164,235 |

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

### 1 Nature of business and going concern

MyndTec Inc. (the "Company" or "MyndTec") is a medical technology company that researches, develops and distributes innovative therapies designed to improve function, maximize independence and enhance the quality of life for individuals with paralysis due to stroke or spinal cord injury. The Company is incorporated under the Business Corporations Act of Ontario and its head office is located at 1900 Minnesota Court, Suite 122, Mississauga, Ontario, L5N 3C9. The Company became a publicly traded entity on the Canadian Securities Exchange on February 16, 2022 and is listed under the symbol MYTC.

These unaudited interim condensed consolidated financial statements (the "financial statements") have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business as they come due. There is no certainty whether the Company will generate significant revenue or attain profitable operations in the near future, as it incurred a net and comprehensive loss of $628,939 and had a negative cash flow from operating activities of $540,156 for the six-month period ended June 30, 2024. As at June 30, 2024, the Company was in default on its Federal Economic Development Agency loan, with a principal balance of $429,842 (note 10), and with respect to a claim by its former lawyer for $715,652 in fees (note 7).

The Company has accumulated $20,307,705 of losses as of June 30, 2024 and its ability to continue as a going concern is dependent on it raising future required capital, bringing its products to market and achieving and maintaining profitable operations. The outcome of these matters cannot be predicted at this time. As a result, there exists a material uncertainty which creates significant doubt regarding the Company's ability to continue as a going concern. These financial statements do not include any adjustments and classifications of assets and liabilities, which might be necessary should the Company be unable to continue its operations. Such adjustments could be material.

### 2 Basis of presentation

#### *Statement of compliance*

These financial statements have been prepared by Management in accordance with International Accounting Standards ("IAS") 34, Interim Financial Reporting. These financial statements do not include all of the information required for full annual consolidated financial statements and should be read in conjunction with the most recent annual consolidated financial statements of the Company, including the notes thereto, for the year ended December 31, 2023.

These consolidated financial statements were approved and authorized for issuance by the Board of Directors of the Company on August 20, 2024.

#### *Basis of consolidation*

The financial statements include the accounts of the Company and its wholly owned subsidiary, MyndTec US Inc. which was incorporated by the Company in the United States on October 10, 2018. As at June 30, 2024. December 31, 2023 and June 30, 2023, the US subsidiary is inactive.

The financial statements of the subsidiary are prepared for the same reporting period as the parent company, using consistent accounting policies, and the subsidiary is fully consolidated from its date of formation. All intercompany balances, transactions and unrealized gains and losses resulting from intercompany transactions are eliminated on consolidation.

#### *Functional currency and presentation currency*

These financial statements are presented in Canadian dollars ("CAD dollars"). The Company's functional currency is Canadian dollars, and the functional currency of the Company's wholly owned subsidiary is the United States dollar.

#### *Use of estimates and judgements*

The preparation of these financial statements in conformity with IFRS requires management to make estimates, judgments and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.

Estimates are based on management's best knowledge of current events and actions the Company may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

## 2 Basis of presentation (continued)

The following are the critical judgments, apart from those involving estimations, that management has made in the process of applying the Company's accounting policies and that have the most significant effect on the amounts recognized in the consolidated financial statements:

- ***Going concern***
  Judgement is required in determining if disclosure of a material uncertainty related to events or conditions which cast significant doubt on the Company's ability to continue as a going concern is required.

  The estimates used by management in reaching this conclusion are based on information available as of the date of these audited consolidated financial statements were authorized for issuance and included an internally generated cash flow forecast. Accordingly, actual results could differ from those estimates and resulting variances may be material to management's assessment.

  As indicated in notes 1, 7, 10 and 18, a material uncertainty exists which creates significant doubt regarding the Company's ability to continue as a going concern. These financial statements do not include any adjustments or reclassifications of assets and liabilities, which might be necessary should the Company be unable to continue its operations. Such adjustments could be material.

- ***Stock options and warrants***
  The Company uses the Black-Scholes valuation model to determine the fair value of stock option awards granted and warrants granted in conjunction with the share capital subscriptions. The fair value of the warrants granted in conjunction with the issuance of convertible debentures were determined using the Cox-Rubenstein Binomial model. Estimates are required for inputs to this model including the fair value of the underlying shares, the expected life of the option, volatility, expected dividend yield, forfeiture rates and the risk-free interest rate. Variation in actual results for any of these inputs will result in a different value of the share option realized from the original estimate. The assumptions and estimates used are further outlined in note 13.

- ***Fair value of financial instruments***
  The individual fair values attributable to the different components of a financing transaction, notably loans and borrowings and convertible debentures are determined using valuation techniques. The Company uses judgment to select the methods used to make certain assumptions and in performing the fair value calculations in order to determine the values attributable to each component of a transaction at the time of their issuance. When determining the discount rate used to estimate the fair value of government loans, the Company considers market conditions and other internal and external factors as well as third-party financing agreements entered into by the Company. In determining the fair value of the Health Technology Exchange loan, the Company uses judgment to estimate the future loan repayments based on projected future revenue. These valuation estimates could be significantly different because of the use of judgment and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market.

- ***Income taxes***
  The Company computes an income tax provision in each of the tax jurisdictions in which it operates. Actual amounts of income tax expense only become final upon filing and acceptance of the tax return by the relevant tax authorities, which occurs subsequent to the issuance of the consolidated financial statements. Additionally, estimation of income taxes includes evaluating the recoverability of deferred tax assets against future taxable income based on an assessment of the ability to use the underlying future tax deductions before they expire. To the extent that estimates of future taxable income differ from the tax return, earnings would be affected in a subsequent period.

  In determining the amount of current and deferred tax, the Company considers the impact of uncertain tax positions and whether additional taxes and interest may be due. This assessment relies on estimates and assumptions and may involve a series of judgments about future events. New information may become available that causes the Company to change its judgment regarding the adequacy of existing tax liabilities; such changes to tax liabilities will impact tax expense in the period that such a determination is made.

- **Revenue recognition**
  The Company recognizes revenue on the transfer of promised services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those services by applying the following steps:
  - identify the contract with a customer;
  - identify the performance obligations in the contract;
  - determine the transaction price;
  - allocate the transaction price to the performance obligations; and,
  - recognize revenue when, or as, the Company satisfies a performance obligation.

## 2 Basis of presentation (continued)

***Use of estimates and judgements (continued)***

- **Revenue recognition (continued)**
  Revenue represents the amount the Company expects to receive for products and services in its contracts with customers, net of discounts and sales taxes. The Company derives treatment revenue based upon the use of the Company's MyndMove devices by treatment clinics; as well as the sale of its products and supplies to research institutions and treatment clinics. Treatment revenue is recognized on a monthly basis as services are provided. The sale of its products and supplies is recognized when delivered to the customer and all performance obligations have been satisfied. The sale of extended warranties is deferred and recognized over the warranty period.

  The Company recognizes revenue upon transfer of control of products or services to customers at an amount that reflects the consideration the Company expects to receive in exchange for the products or services transferred. The Company evaluates contracts with customers to determine the appropriate performance obligations for revenue recognition purposes based on whether the product or service is distinct from some or all of the other products or services in the arrangement. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's promise to transfer the good or service is separately identifiable from other promises in the contractual arrangement with the customer. Non-distinct products and services are combined with other goods or services until they are distinct as a bundle and therefore form a single performance obligation.

  The Company determines the transaction price at the outset of each arrangement and the total consideration is allocated to the distinct performance obligations based on their relative fair value. The Company has determined that the recurring services promised in a contract with a customer represent a series of distinct services that are substantially the same and have the same pattern of transfer over time to the customer and each delivery of service is accounted for as a single distinct performance obligation.

  The timing of revenue recognition and the contractual payment schedules often differ, resulting in some contractual payments being billed prior to the commencement of service. These amounts that are billed, but not earned, are recognized as deferred revenue in the consolidated statements of financial position. When products or services have been transferred to customers and revenue has been recognized, but not billed, the Company recognizes and includes these amounts as unbilled trade receivables in the consolidated statements of financial position.

## 3 Trade and other receivables

The aging of trade and other receivables net of expected credit losses, as at June 30, 2024 and December 31, 2023 were as follows:

| | June 30 2024 | December 31 2023 |
|---|---|---|
| Trade receivables | | |
| 0 - 30 days | $ 3,316 | $ 4,118 |
| 31-90 days | 1,202 | 5,134 |
| Over 90 days | 935 | 30 |
| | $ 5,453 | $ 9,282 |
| Commodity taxes | 6,144 | 4,245 |
| | $ 11,597 | $ 13,527 |

The Company provides for expected credit losses based on its assessment of probability of specific losses, estimates of future individual exposures and provisions based on historical experience. During the six-month period ended June 30, 2024 the Company recorded $nil (June 30, 2023 - $nil) expected credit losses.

## 4 Inventories

The following are the Company's inventories as at June 30, 2024 and December 31, 2023:

| | June 30 2024 | December 31 2023 |
|---|---|---|
| Production parts and clinical supplies | $ 48,376 | $ 41,717 |
| Finished devices | 91,020 | 142,701 |
| | $ 139,396 | $ 184,418 |

During the six-month period ended June 30, 2024, inventory of $23,283 was recorded to cost of goods sold (June 30, 2023 - $15,266. During the six-month period ended June 30, 2024, the Company recognized a $29,496 write down of inventory (June 30, 2023 - $nil).

## 5 Right-of-use asset and lease obligations

Changes in the right-of-use asset and lease obligation for the six-month period ended June 30, 2024 and year ended December 31, 2023 are as follows:

***Right-of-use asset***

| | June 30 2024 | December 31 2023 |
|---|---|---|
| **Cost** | | |
| Balance - beginning and end of period | $ 70,056 | $ 70,056 |
| **Accumulated depreciation** | | |
| Balance - beginning of period | 56,434 | 33,082 |
| Amortization | 11,676 | 23,352 |
| Balance - end of period | 68,110 | 56,434 |
| **Net book value - end of period** | $ 1,946 | $ 13,622 |

***Lease obligation***

| | June 30 2024 | December 31 2023 |
|---|---|---|
| **Balance - beginning of period** | $ 6,253 | $ 31,213 |
| Accreted interest expense (note 16) | 126 | 2,518 |
| Lease payments | (6,379) | (27,478) |
| **Balance - end of period** | - | 6,253 |
| Less current portion (note 9) | - | 6,253 |
| **Long-term portion** | $ - | $ - |

The Company's right-of-use asset relates to the Company's three-year office premises lease that commenced on August 1, 2021. The Company's fair value estimate of this office lease addition and initial liability was $70,056, utilizing an incremental borrowing rate of 13.5%. Variable lease payments for the six-month period ended June 30, 2024 were $16,547 (June 30, 2023 – $16,204), recognized in general and administrative expenses in the interim condensed consolidated statements of loss and comprehensive loss.

## 6 Equipment

| Net Book Value (NBV) | Computers Software and Equipment | Tooling | Treatment Devices | Total |
|---|---|---|---|---|
| **Balance, December 31, 2022** | **$ 6,405** | **$ 44,469** | **$ 152,176** | **$ 203,050** |
| Depreciation during the period | (1,819) | (6,141) | (24,863) | (32,823) |
| **Balance, June 30, 2023** | **$ 4,586** | **$ 38,328** | **$ 127,313** | **$ 170,227** |
| Depreciation during the period | (1,830) | (38,328) | (24,852) | (65,010) |
| **Balance, December 31, 2023** | **$ 2,756** | **$ -** | **$ 102,461** | **$ 105,217** |
| Depreciation during the period | (372) | - | (10,242) | (10,614) |
| **Balance, June 30, 2024** | **$ 2,384** | **$ -** | **$ 92,219** | **$ 94,603** |
| **NBV As at December 31, 2023** | | | | |
| Cost | $ 6,661 | $ - | $ 158,170 | $ 164,831 |
| Accumulated depreciation | (3,905) | - | (55,709) | (59,614) |
| Net book value | **$ 2,756** | **$ -** | **$ 102,461** | **$ 105,217** |
| **NBV As at June 30, 2024** | | | | |
| Cost | $ 6,661 | $ - | $ 158,170 | $ 164,831 |
| Accumulated depreciation | (4,277) | - | (65,951) | (70,228) |
| Net book value | **$ 2,384** | **$ -** | **$ 92,219** | **$ 94,603** |

## 7 Trade and other payables

The following are included in trade and other payables as at June 30, 2024 and December 31, 2023:

| | June 30 2024 | December 31 2023 |
|---|---|---|
| Trade and other payables | $ 189,589 | $ 239,155 |
| Warranty provision | 12,148 | 13,310 |
| Deferred payment agreement | 550,000 | 550,000 |
| Legal fees incurred after January 24, 2022 | 165,652 | 165,652 |
| | $ 917,389 | $ 968,117 |

### Deferred Payment Agreement

On December 31, 2021, the Company entered into an agreement with its former legal firm, which was made in settlement of amounts payable by the Company for services provided in 2021 and up to January 24, 2022, that related to the preparation of the Company's non-offering prospectus and execution of its February 2022 private placement. The agreement provided for deferral of $339,000 of fees, to be paid at $2,500 per month from February 1, 2022 to June 1, 2023 plus $296,500 due and payable on June 30, 2023. In the event the Company closes a private placement or public offering, the Company was required to pay down the outstanding balance as follows:

1. if the offering is less than $3 million, the payment will be 5% of the original deferred balance;
2. if the offering is $3 million or more, the payment will be for the outstanding balance.

Interest was to be accrued on the balance beginning January 24, 2022 at an annual rate equal to the Royal Bank of Canada prime rate plus 5%, calculated and compounded monthly. Conditional upon the Company respecting the payment terms, the interest was to be waived.

### 7 Trade and other payables (continued)

Loan payments of $29,450 were made in 2023 and the remainder of the loan was due for payment by June 30, 2023.

On June 30, 2023, the entire deferred payment balance became due; the Company was unable to pay this obligation; and, the Company became in default of this agreement. As at December 31, 2023, the former legal firm demanded its full entitlement under the agreement, which required the Company to expense $255,792 of penalties, included in public company costs in the consolidated statement of net and comprehensive loss, and has charged the Company $14,658 in interest expense, creating a total addition to the Company's losses of $270,450 in the year ended December 31, 2023.

The Company has not accrued any interest on this loan from June 1, 2023 to June 30, 2024, given the creditor has not made additional claims and the Company has made significant counterclaims.

**Disputed expenses and Company's Court Assessment**

On April 6, 2022, the Company obtained an Order for Assessment from the Ontario Superior Court of Justice to assess $198,570 of legal fees, of which the Company had already paid $32,918 and $165,652 remains unpaid. The Company intends to add the fore-noted $270,450 of interest and penalties to this Assessment, if it is unable to make alternate settlement arrangements.

**Deferred Payment Agreement and Disputed Expenses.**

The Company does not have funds to settle the $550,000 of deferred payment agreement obligations or the $165,652 of disputed expenses and has asked its former legal firm to accept a lesser settlement, similar to the arrangement it made with the Health Technology Exchange or, perhaps, in cash (note 10).

On December 21, 2023 the Company's former legal firm filed a Statement of Claim with the Ontario Superior Court of Justice, in the amount of $715,202 to collect their fees. On January 29, 2024, the Company filed a Statement of Defense and Counterclaim with respect to the December 21, 2023 Claim for Damages, which was filed against the Company by the Company's former legal firm.

As of June 30, 2024, there have been no mediation meetings or other formal proceedings in respect of this matter. The Court has provided a May 5, 2025 date for the first court date on which the parties will be able to deal with this matter.

### 8 Deferred revenue

Current plus long-term deferred revenue was $42,500 as at June 30, 2024 (December 31, 2023 - $51,000), net of $8,500 of income recognized in the six-month period ended June 30, 2024 (June 30, 2023 - $8,500). The deferred revenue as at June 30, 2024 and December 31, 2023 relates to a five-year extended warranty for the engineering, manufacturing and delivery of devices to a research facility, the KITE Research Institute at the University Health Network, in Toronto, Canada, which is significantly influence by a director of the Company (note 12).

### 9 Current portion of long-term liabilities

The current portion of long-term liabilities as at June 30, 2024 and December 31, 2023 includes:

| | June 30 2024 | December 31 2023 |
|---|---|---|
| **Payable in cash** | | |
| Federal Economic Development Agency (note 10) | $ 429,842 | $ 419,257 |
| Health Technology Exchange (note 10) | - | 1 |
| Canadian Emergency Buisiness Account (note 10) | - | 30,000 |
| Total government loans | 429,842 | 449,258 |
| Lease obligations (note 5) | - | 6,253 |
| Other long-term debt (note 11) | 5,068 | - |
| | $ 434,910 | $ 455,511 |

## 10 Government loans

Government loans as at June 30, 2024 and December 31, 2023 include:

| | June 30 2024 | December 31 2023 |
|---|---|---|
| Federal Economic Development Agency (FEDA) | $ 429,842 | $ 419,257 |
| Health Technology Exchange (HTX) (note 18) | - | 1 |
| Canadian Emergency Buisiness Account (CEBA) | - | 30,000 |
| | 429,842 | 449,258 |
| Less current portion (note 9) | 429,842 | 449,258 |
| **Long-term portion** | $ - | $ - |

### Federal Economic Development Agency of Southern Ontario (FEDA) loan

The FEDA loan is unsecured, non-interest bearing and it provided initial financing of $919,518. On December 3, 2021, the payment terms for this loan were amended and, as at June 30, 2024, the principal balance outstanding of this loan is $429,842 (December 31, 2023 – $419,257), due on demand.

On December 1, 2022, the Company defaulted on a payment due to FEDA and on December 31, 2022 the Company exhausted the allowed time to cure the default and the loan became immediately due and payable. No payments have been made since November 1, 2022.

During the six-month period ended June 30, 2024, the Company recognized $10,585 (June 30, 2023 – $nil) of accretion expense (note 16) and the Company made repayments of $nil (June 30, 2023 - $nil).

### Health Technology Exchange (HTX) loan

The HTX loan was unsecured, required interest at 3.1% per annum, was repayable based on 10% of certain preceding year gross revenue and provided initial financing of $749,600. As at June 30, 2024, the principal balance outstanding on this loan is $nil, pursuant to a settlement agreement with HTX, (December 31, 2023 – $378,059). During the six-month period ended June 30, 2024, the Company made a cash repayment of $nil (June 30, 2023 – $nil) and the Company recognized $nil (June 30, 2023 – $7,543) of accretion expense (note 16) on this loan.

On July 6, 2023 the Company closed a settlement agreement with the Health Technology Exchange whereby the Company's repayment obligation of $756,121 was fixed as of May 29, 2023 and partially repaid by the issuance of 540,088 in common shares (note 14) at a market price of $0.70 per share, for a total of $378,062. The $378,059 remainder of the obligation was forgiven, subject to the condition that the Company's MyndMove product revenues did not exceed $1,000,000 in the twelve-month period ended May 29, 2024.

Pursuant to the Company's July 6, 2023 settlement agreement with HTX, the Company has determined the May 29, 2024 fair value of the HTX loan to be $nil (December 31, 2023 - $1 for the contingent forgiveness of $378,058). On May 29, 2024, the Company recorded a fair value adjustment gain of one dollar ($1) (June 30, 2023 - adjustment loss of $105,436 and for six-month period).

### Federal Canadian Emergency Business Account (CEBA) loan

The Federal CEBA loan is part of the Canadian federal government's support program in response to the COVID-19 pandemic, wherein the Company was able to obtain a $30,000 non-interest-bearing loan, net of a $10,000 forgivable amount. This loan was paid on January 22, 2024 to assure the $10,000 forgiveness.

During the six-month period ended June 30, 2024, the Company recognized $nil (June 30, 2023 – $801) of accretion expense on this loan (note 16) and repaid $30,000 (June 30, 2023 – $nil) of the principal.

## 10 Government loans (continued)

**A reconciliation of the government loans is as follows:**

| | June 30 2023 | December 31 2023 |
|---|---|---|
| **Balance - beginning of period** | $ 449,258 | $ 702,976 |
| Loan payments | (30,000) | - |
| Conversion to equity | - | (378,062) |
| Accretion expense (note 16) | 10,585 | 18,908 |
| Fair value adjustment of government loans | (1) | 105,436 |
| **Balance - end of period** | 429,842 | 449,258 |
| Less current portion (note 9) | 429,842 | 449,258 |
| **Long-term portion** | $ - | $ - |

## 11 Other long-term debt

On January 22, 2024, the Company's Canadian Emergency Business Account loan (note 10) was repaid from the proceeds of a loan from the Royal Bank of Canada (RBC). The new $30,000 RBC loan is repayable in equal amounts over 60 months, commencing on February 22, 2024, with interest at RBC prime plus 2.84%.

During the six-month period ended June 30, 2024, the Company recognized $1,218 of interest expense (note 16) and repaid $1,972 of the principal on this loan. At June 30, 2024 the outstanding principal was $28,028.

## 12 Related party balances and transactions

During the six-month periods ended June 30, 2024 and 2023, the Company recognized treatment revenues and device sales revenues from LBB Applied Technology Inc., a significant shareholder of the Company and the Company's distributor in the USA. that was previously able to nominate one director to the Company's Board of Directors. These transactions were made in the normal course of business.

The Company has a shareholder and director, who is employed by the KITE Research Institute at the University Health Network in Toronto, Canada (KITE), an Institution over which he has significant influence and to which the Company is committed to a long-term license agreement (note 18), requiring the semi-annual payment of royalty fees. In addition, the Company has entered into contracts with this Institution to sell MyndMove devices, which have been modified for research purposes; and to purchase research and development (R&D) services.

In 2017, the Board approved the remuneration of a director and shareholder, for services as interim CEO provided to the Company in addition to his role as director. As at June 30, 2023, the entire $75,000 amount remained unpaid and was included in trade and other payables. In the fourth quarter of 2023, the amount was forgiven by the director and shareholder and recorded as a reduction of general and administration salaries and benefits.

## 12 Related party balances and transactions (continued)

A summary of the Company's related party transactions and balances are as follows:

| | June 30 | | December 31 |
|---|---|---|---|
| | 2024 | 2023 | 2023 |
| **Revenue during the six-month period ended** | | | |
| Sale of devices and parts | 29,147 | 2,279 | |
| | $ 29,147 | $ 2,279 | |
| **Expenses during the six-month period ended** | | | |
| Share-based compensation for directors and senior officers | $ 21,035 | $ 32,182 | |
| Salaries, fees and benefits for directors and senior officers | 176,786 | 214,420 | |
| License fees | 3,075 | 1,897 | |
| | $ 200,896 | $ 248,499 | |
| **Assets - as at the date specified** | | | |
| Accounts receivable | $ 1,854 | $ 3,616 | $ 5,360 |
| **Liabilities - as at the date specified** | | | |
| Due to director | $ - | $ 75,000 | $ - |
| License fees and expenses payable | $ 90,296 | $ 84,476 | $ 96,759 |
| Deferred revenue | $ 42,500 | $ 59,500 | $ 51,000 |

## 13 Share capital, warrants and stock options

The Company is authorized to issue an unlimited number of common shares. The following is a summary of the Company's issued securities:

| | Common Shares | Warrants | Stock Options | Fully Diluted Total |
|---|---|---|---|---|
| **Balance, December 31, 2022** | **21,838,500** | **5,998,239** | **1,115,000** | **28,951,739** |
| Rights forfeited or expired | - | (1,259,535) | (150,000) | (1,409,535) |
| Options issued | - | - | 525,000 | 525,000 |
| Private placement | 1,259,038 | 1,259,038 | - | 2,518,076 |
| **Balance, June 30, 2023** | **23,097,538** | **5,997,742** | **1,490,000** | **30,585,280** |
| Rights forfeited or expired | - | - | (5,000) | (5,000) |
| Debt conversion (note 10) | 540,088 | - | - | 540,088 |
| Private placements | 361,705 | 361,705 | - | 723,410 |
| **Balance, December 31, 2023** | **23,999,331** | **6,359,447** | **1,485,000** | **31,843,778** |
| Rights forfeited or expired | - | - | (25,000) | (25,000) |
| Options issued | - | - | 37,500 | 37,500 |
| Private placements | 723,694 | 723,694 | - | 1,447,388 |
| **Balance, June 30, 2024** | **24,723,025** | **7,083,141** | **1,497,500** | **33,303,666** |

## 13 Share capital, warrants and stock options (continued)

***2024 Private Placements***

On February 13, 2024, March 19, 2024, May 27, 2024 and June 24, 2024 - the Company completed total Private Placements of 723,694 Units, with its largest shareholder, at $0.75 per Unit, for a total of $542,770. Each Unit was comprised of one common share and one warrant. The warrants have an exercise price of $0.90 per warrant and expire three years from the date of issuance.

The subscriber ultimately received 723,694 common shares of the Company and 723,694 warrants to acquire common shares of the Company at $0.90. The warrants expire three years after the respective issue dates. Of the $506,514 in net proceeds, $160,982 was allocated to the value of the warrants, based on a Black Scholes valuation of the warrants with an exercise price of $0.90; a weighted average estimated $0.50 value of common shares; a weighted-average volatility rate of 91.0%; an expected 3-year life for the warrants; and a weighted-average risk-free interest rate of 3.94%.

***2023 Private Placements***

On January 11, 2023 and May 23, 2023, the Company completed Private Placements of 1,259,038 Units, in total, with its two largest shareholders, at $0.75 per Unit, for a total of $944,280. On November 3, 2023 and December 20, 2023, the Company completed Private Placements of 361,705 Units, in total, with its largest shareholder, at $0.75 per Unit, for a total of $271,279. Each Unit was comprised of one Common share and one warrant. The warrants have an exercise price of $0.90 per warrant and expire three years from the date of issuance.

The subscribers ultimately received 1,620,743 common shares of the Company and 1,620,743 warrants to acquire common shares of the Company at $0.90. The warrants expire January 11, May 23, November 3 and December 20 of 2026. Of the $1,152,625 in net proceeds, $413,247 was allocated to the value of the warrants, based on a Black Scholes valuation of the warrants with an exercise price of $0.90; a weighted average estimated $0.77 value of common shares; a weighted-average volatility rate of 91.88%; an expected 3-year life for the warrants; and a weighted-average risk-free interest rate of 3.77%.

**Debt Conversion to Equity and Forgiveness of Government Debt**

On July 6, 2023, the Company closed a settlement agreement with the HTX (note 10), whereby the Company's repayment obligation of $756,121 was fixed as of May 29, 2023 and then, partially repaid by the issuance of 540,088 in common shares, at $0.70 per share, for a total of $378,062.

The $378,059 remainder of the obligation was forgiven, subject to the condition that the Company's MyndMove product revenues do not exceed $1,000,000 in the twelve-month period ended May 29, 2024. The Company has recorded the fair value of this outstanding obligation at one dollar ($1), as explained in notes 11 and 18 of the Company's financial statements.

***Warrants and Options***

On June 30, 2024, the Company has 7,083,141 of fully vested warrants outstanding, exercisable into one common share per warrant, as follows:

- 4,738,704 at an exercise price of $1.00, that expire on February 16, 2027.
- 762,932 at an exercise price of $0.90, that expire in the six-month period ending March 31, 2026
- 857,811 at an exercise price of $0.90, that expire in the nine-month period ending December 31, 2026
- 723,694 at an exercise price of $0.90, that expire in the six-month period ending June 30, 2027

On June 30, 2024, the Company had 1,497,500 options outstanding, with a weighted average exercise price of $0.89 and weighted average remaining life of 7.22 years. 1,104,167 of the options are fully vested.

The Company estimated the fair value of the stock options granted in 2024 and 2023 using the Black-Scholes option pricing model with the following weighted average assumptions:

| | 2024 | 2023 | |
|---|---|---|---|
| | April 25 | June 15 | May 17 |
| Options | 37,500 | 25,000 | 500,000 |
| Exercise Price | $0.75 | $0.70 | $0.75 |
| Estimated share price value | $0.50 | $0.70 | $0.70 |
| Volatility | 113.26% | 112.87% | 113.26% |
| Expected life in years | 5 | 10 | 10 |
| Risk-free interest rate | 3.89% | 3.33% | 3.09% |
| Dividend yield | nil | nil | nil |
| Estimated value per option | $0.385 | $0.656 | $0.655 |
| Total valuation | $14,442 | $16,402 | $327,286 |

Due to the absence of Company specific volatility rates, the Company chose comparable companies in a similar industry.

In the six-month period ending June 30, 2024 the Company recorded $53,120 (June 30, 2023 – $73,746) of share-based compensation expense, related to stock options, in the consolidated statement of loss and comprehensive loss, using the graded vesting method,

## 14 Breakdown of expenses by nature, for the six-month period ending:

| | 2024 | 2023 |
|---|---|---|
| **General and administration** | | |
| Salaries and benefits (note 12 and 15) | $ 187,992 | $ 187,347 |
| Accounting, legal and professional fees | 94,184 | 101,463 |
| Technology expense | 30,676 | 39,029 |
| Additional rent | 16,547 | 16,204 |
| Insurance | 41,176 | 60,225 |
| Other expenses | 17,216 | 5,150 |
| **Total general and administrstion** | $ 387,791 | $ 409,418 |
| | | |
| **Research and development** | | |
| Salaries and benefits (note 15) | $ 94,843 | $ 129,375 |
| Patent expenses | 10,725 | 31,720 |
| Other development expenses | 2,159 | 78,579 |
| **Total research and development** | $ 107,727 | $ 239,674 |

## 15 Salaries and benefits, for the six-month periods ending:

| | 2024 | 2023 |
|---|---|---|
| General and administration (note 14) | $ 187,992 | $ 187,347 |
| Research, development and quality control (note 14) | 94,843 | 129,375 |
| Selling and marketing | - | 35,005 |
| **Total salaries and benefits** | $ 282,835 | $ 351,727 |

## 16 Interest and accretion expenses, for the six-month periods ending:

| | 2024 | 2023 |
|---|---|---|
| Government loans (note 10) | | |
| FEDA | $ 10,585 | $ - |
| HTX | - | 7,543 |
| CEBA | - | 1,626 |
| Total government loans | 10,585 | 9,169 |
| Lease obligation (note 5) | 126 | 1,641 |
| **Total accretion expense** | 10,711 | 10,810 |
| Other long-term debt (note 11) | 1,218 | - |
| Short term interest | (6) | 12,385 |
| **Total interest and accretion expense** | $ 11,923 | $ 23,195 |
| Government loans | | |
| FEDA (note 10) | $ - | $ - |
| HTX (note 10) | (1) | 105,436 |
| CEBA (note 10) | - | - |
| **Total change in fair value** | $ (1) | $ 105,436 |

## 17 Government grants and tax credits

### Scientific research and experimental development tax credits

In the past, the Company has made claims for SR&ED deductions and related expenses for income tax purposes, based on the applicable legislation in the Income Tax Act (Canada). During the year ended December 31, 2023, the Company received and recorded $174,148 of SR&ED claims, related to the December 31, 2021 and February 15, 2022 tax periods. As of February 16, 2022, when the Company became publicly listed, only qualifies for limited cash refundable SR&ED credits. Since that date, no subsequent income has been recorded

## 18 Commitments and contingencies

The Company is in default of its unsecured obligations to its former legal firm (note 7) and the FEDA (note 10), for which it does not have the funds to repay. As of June 30, 2024, the Company's only foreseeable option to settle these $1,145,494 of obligations is to issue Company securities. Otherwise, the creditors might be inclined to commence legal proceedings. These obligations are an impediment to the Company's ability to complete future financings, which creates a material uncertainty and a going concern risk (note 1) for the Company.

Of the Company's existing outstanding options (note 13), 260,000 options with a Black Scholes value of $170,189 and an expiry date of May 17, 2033 will vest and the value thereof will be recognized at such time as the Option Holder successfully introduces an acquisition to the Company, as specified in the respective contract between the parties.

On August 29, 2012, the Company entered into an agreement with a health services institution whereby it granted the Company an exclusive worldwide license to commercialize certain intellectual property related to a functional electrical stimulation device and system; for which the Institution received 400,000 of the Company's common shares, with a fair value of $400,000. In addition, the Company is committed to paying a cumulative royalty on the net sales of stimulators used to treat motor dysfunction, as follows:

- 0% on the first $1,000,000 cumulative net sales;
- 4% on the cumulative net sales exceeding $1,000,000 but not greater than $7,500,000; and,
- 1% on the cumulative net sales exceeding $7,500,000.

The amount of these fees for the six-month periods ended June 30, 2024 and 2023 are disclosed in note 12.

The Company's current lease commitments, expiring July 31, 2024, are disclosed in Note 5. The Company has renewed that lease for another one-year period, effective August 1, 2024 - for a total fixed cost of $30,855, plus variable common area costs, for the extra year. The lease renewal will not be capitalized, because of the short-term duration of the additional term.

## 19 Capital Management

The Company's capital management objectives are to maintain financial flexibility in order to pursue its product development and commercialization strategy, and ultimately provide long-term returns to its shareholders. This strategy relies significantly on the Company's ability to demonstrate growing efficacy creation in its medical devices, in order to convince potential investors to invest more capital in the Company's development efforts.

The Company defines capital as the aggregate of its shareholder equity and borrowings.

The Company manages its capital structure in accordance with changes in economic conditions. In order to maintain or adjust its capital structure, the Company may elect to issue or repay financial liabilities, issue shares, repurchase shares, pay dividends or undertake any other activities as deemed appropriate under the specific circumstances. The Company is not subject to any externally imposed capital requirements. Management reviews its capital management approach on an ongoing basis. There were no material changes to this approach during the six-month period ending June 30, 2024 and year ended December 31, 2023.

## 20 Financial instruments and risk management

***Credit risk***
Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from deposits with banks and outstanding receivables. The Company trades only with recognized, creditworthy third parties. The Company performs credit checks for all customers who wish to trade on credit terms.

The Company does not hold any collateral as security but mitigates this risk by dealing only with what management believes to be financially sound counterparties and, accordingly, does not anticipate significant loss for non-performance.

Credit loss impairment is determined based upon review of specific accounts as the Company does not have significant historical uncollectable receivables. As at June 30, 2024, the Company had $2,137 in overdue trade and other receivables (June 30, 2023 – $5,779).

***Liquidity risk***
Liquidity risk is the risk the Company will not be able to meet its financial obligations as they come due. The Company's exposure to liquidity risk is dependent on the Company's ability to raise additional financing to meet its commitments and sustain operations. The Company mitigates liquidity risk by management of working capital, cash flows, the issuance of share capital and if desired, the issuance of debt. The Company's trade and other payables are all due within twelve months from the date of these consolidated financial statements.

If unanticipated events occur that impact the Company's ability to meet its forecast and continue to fund customer acquisition cost, research and development, and administrative requirements, the Company may need to take additional measures to increase its liquidity and capital resources, including obtaining additional debt or equity financing or strategically altering the business forecast and plan. In this case, there is no guarantee that the Company will obtain satisfactory financing terms or adequate financing. Failure to obtain adequate financing on satisfactory terms could have a material adverse effect on the Company's results of operations or financial condition.

The Company is obligated to the following contractual maturities of undiscounted cash flows as at June 30, 2024:

| | Payments Due | | | |
|---|---|---|---|---|
| | Less than 1 year | 2 - 3 years | After 3 years | Total |
| Trade and other payables | $ 917,389 | $ - | $ - | $ 917,389 |
| Government loans | 434,910 | - | - | 434,910 |
| Other long-term debt | 5,068 | 11,502 | 12,646 | 29,216 |
| | $ 1,357,367 | $ 11,502 | $ 12,646 | $ 1,381,515 |

## 20 Financial instruments and risk management (continued)

***Market risk***

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: foreign currency risk, interest rate risk and other price risk:

- **Foreign currency risk** arises on financial instruments that are denominated in a currency other than the functional currency in which they are measured. The Company's primary exposure with respect to foreign currencies is from United States dollar denominated cash, trade and other receivables, and trade and other payables. As at June 30, 2024, a 1% change in the foreign exchange rates would result in a $1,071 impact to the financial statements (June 30, 2023 - $562).
- **Interest rate risk** is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to interest rate risk as at June 30, 2024 and December 31, 2023 because all of its indebtedness is at fixed rates.
- **Other price risk** is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. The Company is not exposed to other price risk as at June 30, 2024 and December 31, 2023.

***Fair values***

The carrying values of cash and cash equivalents, trade and other receivables excluding HST, trade and other payables excluding HST, and lease obligations are considered representative of their respective fair values due to the short-term period to maturity. The government loans approximate their fair value as the interest and discount rates are consistent with the current rates offered by the Company for its loans with similar terms. The Company does not use derivative financial instruments to manage this risk.

Financial instruments recorded at fair value on the consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The Company categorizes its fair value measurements according to a three-level hierarchy. The hierarchy prioritizes the inputs used by the Company's valuation techniques. A level is assigned to each fair value measurement based on the lowest-level input significant to the fair value measurement in its entirety. The three levels of the fair value hierarchy are defined as follows:

- **Level 1** – Unadjusted quoted prices as at the measurement date for identical assets or liabilities in active markets.
- **Level 2** – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
- **Level 3** – Significant unobservable inputs that are supported by little or no market activity. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The fair value hierarchy requires the use of observable market inputs whenever such inputs exist. A financial instrument is classified to the lowest level of the hierarchy for which a significant input has been considered in measuring fair value. During the year, there were no transfers of amounts between levels. The fair value of derivative and warrant liabilities and HTC government loan are determined using level 3 inputs.

Financial instruments measured at fair value using level 3 inputs:

| | **Valuation technique** | **Significant unobservable inputs** | **Inter-relationship between significant unobservable inputs and fair value** |
|---|---|---|---|
| HTC government loan | Discounted cash flows (note 11) | - Discount rate<br>- Expected timing of repayments based on revenue forecast | An increase revenue growth or decrease in discount rate would increase the fair value of the HTC government loan. |

## 21 Segmented information

The Company reports segment information based on internal reports used by the chief operating decision maker ("CODM") to make operating and resource decisions and to assess performance. The CODM is the Chief Executive Officer.

The Company has revenues from sales in Canada and from Canada to the United States and Malasia. The Company has one operating segment which includes income related to its MyndMove, MyndSearch (a variation of MyndMove, which has been modified for research purposes) and MyndStep devices. The two types of revenue include: (1) treatment fees, from treatment clinics that use the Company's MyndMove devices and (2) product sales, which are revenues from the sale of MyndMove, MyndSearch or MyndStep devices to clinics or research institutions and the sale of treatment supplies.

All treatment revenue devices are located in Canada. Revenues by geographical location and by services and products, delivered in the six-month periods ended March 31 2024 and 2023, were as follows:

| | 2024 | 2023 |
|---|---|---|
| **Revenue by geographic location of customers** | | |
| Canada | $ 40,010 | $ 56,768 |
| Non-Canadian | 46,312 | 2,279 |
| | $ 86,322 | $ 59,047 |
| **Revenue by services and products delivered** | | |
| Treatment fees | $ 31,150 | $ 35,750 |
| Product sales | 55,040 | 23,165 |
| Other | 132 | 132 |
| | $ 86,322 | $ 59,047 |

## 22 Subsequent events

***Private Placement***

On August,5 2024, the Company received funds and accepted a subscription offer for a non-brokered private placement, from an existing shareholder, of 183,320 Units, at $0.75 per Unit, for a total subscription price of $137,490. Each Unit is comprised of one common share and one warrant. The warrants have an exercise price of $0.90 per warrant and will expire three years after the closing date. This transaction closed on August 12, 2024.